The antiviral drug remdesivir should not be used as a routine treatment for COVID-19 patients in critical care wards, the head of one of the world's top bodies representing intensive care doctors said, in a blow to the drug developed by U.S. firm Gilead.
from CBC | Health News https://ift.tt/3lsPPT6
Aucun commentaire:
Enregistrer un commentaire